THE UTILITY OF SALIVARY AMYLASE AS AN EVALUATION OF M(3) MUSCARINIC AGONIST ACTIVITY IN ALZHEIMERS-DISEASE

被引：15

作者：

SRAMEK, JJ ^{[1
]}

CUTLER, NR ^{[1
]}

HURLEY, DJ ^{[1
]}

SEIFERT, RD ^{[1
]}

机构：

[1] ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285

来源：

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | 1995年 / 19卷 / 01期

关键词：

ALZHEIMERS DISEASE; AMYLASE; LY246708; MUSCARINIC RECEPTORS; XANOMELINE;

D O I：

10.1016/0278-5846(94)00107-S

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

1. In this double-blind, placebo-controlled phase I study of the safety/tolerance of two doses of xanomeline tartrate (100 mg and 115 mg tid) given to 12 AD patients, the authors measured serum amylase, fractionated into pancreatic and salivary isoenzymes, as a potential marker for M(3) activity associated with maximally tolerated dose (MTD). 2. MTD of xanomeline was determined to be 100 mg tid based on intolerable adverse events at 115 mg tid. One patient at the 115 mg tid level presented with moderate hypersalivation and salivary amylase levels 400% of baseline. 3. Overall amylase results were not significant, however a trend in the results for salivary amylase in the 115mg panel suggests that salivary amylase may be a useful marker M(3) activity.

引用

页码：85 / 91

页数：7

共 20 条

[1]

BELIK J, 1983, PEDIATRICS, V71, P585

[2] ALZHEIMERS-DISEASE - A DISORDER OF CORTICAL CHOLINERGIC INNERVATION [J].